New laws needed to govern the use of artificial tools in medicine, the head of the UK’s medical regulator has warned. MHRA chief Lawrence Tallon told the broadcaster that such technology will soon be routinely used within the NHS. His remarks, made in an interview with the public broadcaster, underline a call for lawmakers and regulators to examine whether existing rules are sufficient as clinical systems adopt automated decision-support and diagnostic tools.
The emergence of algorithmic systems in clinical settings raises questions about how products are evaluated, approved and monitored in practice. Regulators will play a role in assessing safety and performance, but the intervention by the head of the MHRA points to a potential legislative gap. Debate is now likely to centre on responsibilities for developers, deployers and healthcare providers as artificial intelligence moves from research and pilots into everyday NHS workflows.
Policy-makers face a range of choices: update existing regulatory frameworks, create new statutory powers, or clarify how current laws apply to software that learns and changes over time. Any change will have practical consequences for procurement, clinical governance and patient data handling. The regulator’s public statement is significant because it signals that regulatory oversight alone, without supplementary legal measures, may not be judged adequate for the technologies being introduced.
As hospitals and services prepare for broader deployment of algorithmic systems, the implications extend beyond technical validation to questions of accountability and public trust. The intervention by Lawrence Tallon and the MHRA closes a loop between technological advance and legal frameworks, prompting a reassessment of how health services, industry and government will manage the next phase of digital innovation in the NHS.
